• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化急性加重的危险因素:一项系统评价和荟萃分析。

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

作者信息

Qiu Meihua, Chen Yuqing, Ye Qiao

机构信息

Department of Occupational Medicine and Toxicology, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

出版信息

Clin Respir J. 2018 Mar;12(3):1084-1092. doi: 10.1111/crj.12631. Epub 2017 Apr 12.

DOI:10.1111/crj.12631
PMID:28332341
Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic disease limited to the lungs. The course of disease varies widely, with some patients experiencing acute respiratory deterioration, a condition called acute exacerbations of IPF (AE-IPF). The risk factors contributing to AE-IPF are unclear. This systematic review and meta-analysis investigated the risk factors for AE-IPF.

METHODS

Studies of risk factors for AE-IPF were identified in Medline, EMBASE and Cochrane databases. Fixed effects models were used to calculate pooled relative risks and weighted mean differences (WMD).The meta-analysis included seven articles involving 14 risk factors for AE-IPF.

RESULTS

Risk factors for AE included reductions in vital capacity (VC; WMD - 10.58, 95% confidence interval (CI) -17.17 to - 3.99), forced vital capacity (FVC; WMD -6.02, 95%CI - 8.58 to - 3.47), total lung capacity (TLC; WMD -4.88, 95%CI -7.59 to - 2.17), and PaO (WMD -4.19, 95%CI -7.66 to -0.71) and a higher alveolar-arterial oxygen difference (AaDO ; WMD 4.4, 95%CI 0.24 to 8.57). Mechanical procedures, higher serum KL-6 concentration and secondary pulmonary hypertension, might be risk factors for AE-IPF. In contrast, age, sex, body mass index (BMI), differences in diffusing lung capacity for carbon monoxide (DLCO), exposure to seasonal variations and air pollution, and virus infection might be unrelated to AE-IPF.

CONCLUSIONS

Poor pulmonary function, mechanical procedures, higher serum KL-6 and secondary pulmonary hypertension were associated with increased risks of AE-IPF.

摘要

背景

特发性肺纤维化(IPF)是一种局限于肺部的慢性进行性纤维化疾病。疾病进程差异很大,一些患者会出现急性呼吸功能恶化,即所谓的特发性肺纤维化急性加重(AE-IPF)。导致AE-IPF的危险因素尚不清楚。本系统评价和荟萃分析对AE-IPF的危险因素进行了研究。

方法

在Medline、EMBASE和Cochrane数据库中检索有关AE-IPF危险因素的研究。采用固定效应模型计算合并相对风险和加权平均差(WMD)。该荟萃分析纳入了7篇涉及AE-IPF 14个危险因素的文章。

结果

AE的危险因素包括肺活量(VC;WMD -10.58,95%置信区间(CI)-17.17至-3.99)、用力肺活量(FVC;WMD -6.02,95%CI -8.58至-3.47)、肺总量(TLC;WMD -4.88,95%CI -7.59至-2.17)、动脉血氧分压(PaO;WMD -4.19,95%CI -7.66至-0.71)降低以及肺泡-动脉氧分压差(AaDO;WMD 4.4,95%CI 0.24至8.57)升高。机械操作、血清KL-样物质6(KL-6)浓度升高和继发性肺动脉高压可能是AE-IPF的危险因素。相比之下,年龄、性别、体重指数(BMI)、一氧化碳弥散量(DLCO)差异、季节变化和空气污染暴露以及病毒感染可能与AE-IPF无关。

结论

肺功能差、机械操作、血清KL-6升高和继发性肺动脉高压与AE-IPF风险增加相关。

相似文献

1
Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.特发性肺纤维化急性加重的危险因素:一项系统评价和荟萃分析。
Clin Respir J. 2018 Mar;12(3):1084-1092. doi: 10.1111/crj.12631. Epub 2017 Apr 12.
2
Pulmonary rehabilitation for interstitial lung disease.间质性肺疾病的肺康复治疗。
Cochrane Database Syst Rev. 2021 Feb 1;2(2):CD006322. doi: 10.1002/14651858.CD006322.pub4.
3
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.环磷酰胺用于治疗结缔组织病相关的间质性肺疾病。
Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2.
4
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.免疫刺激剂与安慰剂在预防慢性支气管炎或慢性阻塞性肺疾病成人恶化中的比较。
Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD013343. doi: 10.1002/14651858.CD013343.pub2.
5
Chronic non-invasive ventilation for chronic obstructive pulmonary disease.慢性阻塞性肺疾病的慢性无创通气。
Cochrane Database Syst Rev. 2021 Aug 9;8(8):CD002878. doi: 10.1002/14651858.CD002878.pub3.
6
The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial.添加兰索拉唑治疗特发性肺纤维化患者的有效性和风险(TIPAL):一项随机安慰剂对照多中心临床试验的研究方案
BMJ Open. 2025 Feb 5;15(2):e088604. doi: 10.1136/bmjopen-2024-088604.
7
Mucolytics for children with chronic suppurative lung disease.用于患有慢性化脓性肺病儿童的黏液溶解剂。
Cochrane Database Syst Rev. 2025 Mar 28;3(3):CD015313. doi: 10.1002/14651858.CD015313.pub2.
8
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.吸入抗生素治疗囊性纤维化肺部加重。
Cochrane Database Syst Rev. 2022 Aug 1;8(8):CD008319. doi: 10.1002/14651858.CD008319.pub4.
9
Risk factors for the onset of pneumothorax in idiopathic pulmonary fibrosis.特发性肺纤维化中气胸发作的危险因素。
Respir Investig. 2025 Sep;63(5):744-748. doi: 10.1016/j.resinv.2025.06.007. Epub 2025 Jun 20.
10
Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.经手术证实为普通型间质性肺炎的特发性肺纤维化新定义急性加重:危险因素与预后
Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):39-46. doi: 10.36141/svdld.v36i1.7117. Epub 2019 May 1.

引用本文的文献

1
Development of a Prediction Model for Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Study of the Korea IPF Cohort Registry.特发性肺纤维化急性加重预测模型的开发:韩国特发性肺纤维化队列登记研究
J Korean Med Sci. 2025 Sep 1;40(34):e212. doi: 10.3346/jkms.2025.40.e212.
2
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease.KL6水平的纵向变化可预测纤维化间质性肺疾病的急性加重。
Sci Rep. 2025 Jul 18;15(1):26061. doi: 10.1038/s41598-025-12236-8.
3
Current advancements in the mechanisms and animal models of acute exacerbation of pulmonary fibrosis: a systematic review.
肺纤维化急性加重机制与动物模型的当前进展:一项系统综述
Front Pharmacol. 2025 May 30;16:1501085. doi: 10.3389/fphar.2025.1501085. eCollection 2025.
4
The Presence of Emphysema in Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer: Impact on Tumor Features, Acute Exacerbation, and Survival.特发性肺纤维化和肺癌患者中肺气肿的存在:对肿瘤特征、急性加重和生存的影响。
J Clin Med. 2025 May 30;14(11):3862. doi: 10.3390/jcm14113862.
5
Role of blood Krebs von Lungen-6 in predicting acute exacerbation in patients with idiopathic pulmonary fibrosis.血液中克雷布斯肺-6在预测特发性肺纤维化患者急性加重中的作用。
PLoS One. 2025 May 30;20(5):e0323784. doi: 10.1371/journal.pone.0323784. eCollection 2025.
6
Acute Exacerbation of Idiopathic Pulmonary Fibrosis in the Setting of Acute Eosinophilic Pneumonia.急性嗜酸性粒细胞性肺炎背景下的特发性肺纤维化急性加重
HCA Healthc J Med. 2025 Feb 1;6(1):11-21. doi: 10.36518/2689-0216.1802. eCollection 2025.
7
Traditional Chinese Medicine Ion Introduction Therapy Reduces the Incidence of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study.中药离子导入疗法降低特发性肺纤维化急性加重的发生率:一项前瞻性队列研究
Int J Gen Med. 2025 Jan 6;18:21-32. doi: 10.2147/IJGM.S498350. eCollection 2025.
8
Acute exacerbations in patients with progressive pulmonary fibrosis.进行性肺纤维化患者的急性加重
ERJ Open Res. 2024 Dec 2;10(6). doi: 10.1183/23120541.00403-2024. eCollection 2024 Nov.
9
Role of telomere dysfunction and immune infiltration in idiopathic pulmonary fibrosis: new insights from bioinformatics analysis.端粒功能障碍和免疫浸润在特发性肺纤维化中的作用:来自生物信息学分析的新见解
Front Genet. 2024 Sep 13;15:1447296. doi: 10.3389/fgene.2024.1447296. eCollection 2024.
10
Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.汇聚途径:间质性肺疾病中的肺动脉高压综述
Life (Basel). 2024 Sep 23;14(9):1203. doi: 10.3390/life14091203.